MOUNTAIN VIEW, Calif, March 2, 2010 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it will report financial results for the fourth quarter and year ended December 31, 2009 after the NASDAQ Market closes on Monday, March 8, 2010.
The company will conduct a conference call and an audio webcast at 1:30pm PT on the same day.
Date: March 8, 2010 Time: 1:30 PM PT
Listen via Internet: http://ir.vivus.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=41185&k=71E88E68
Toll-free: 877-359-2916 International: 224-357-2386
A webcast replay will be available on the VIVUS web site for 30 days.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa(r), has completed phase 3 clinical trials for the treatment of obesity and an NDA was submitted to the FDA in December 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(tm) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(r) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.